Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC cut its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 57.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 123,714 shares of the company’s stock after selling 170,449 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Teva Pharmaceutical Industries were worth $1,292,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the business. Victory Capital Management Inc. increased its position in Teva Pharmaceutical Industries by 21.9% during the fourth quarter. Victory Capital Management Inc. now owns 38,386 shares of the company’s stock worth $401,000 after purchasing an additional 6,886 shares during the last quarter. Transcend Capital Advisors LLC lifted its stake in shares of Teva Pharmaceutical Industries by 13.6% in the 4th quarter. Transcend Capital Advisors LLC now owns 12,543 shares of the company’s stock valued at $131,000 after purchasing an additional 1,500 shares in the last quarter. Truist Financial Corp grew its stake in Teva Pharmaceutical Industries by 1.3% during the fourth quarter. Truist Financial Corp now owns 134,022 shares of the company’s stock worth $1,399,000 after buying an additional 1,766 shares during the period. Element Wealth LLC increased its holdings in Teva Pharmaceutical Industries by 394.8% in the 4th quarter. Element Wealth LLC now owns 65,740 shares of the company’s stock valued at $686,000 after purchasing an additional 52,454 shares in the last quarter. Finally, Duality Advisers LP acquired a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter valued at about $1,621,000. 54.05% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA opened at $15.74 on Thursday. The firm has a market capitalization of $17.64 billion, a price-to-earnings ratio of -33.48, a price-to-earnings-growth ratio of 1.67 and a beta of 1.04. The stock’s fifty day moving average is $13.70 and its 200-day moving average is $11.72. Teva Pharmaceutical Industries Limited has a one year low of $7.09 and a one year high of $16.13. The company has a debt-to-equity ratio of 2.23, a quick ratio of 0.69 and a current ratio of 1.02.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, VP Eric Drape sold 173,261 shares of the business’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $13.05, for a total transaction of $2,261,056.05. Following the sale, the vice president now directly owns 1 shares in the company, valued at approximately $13.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, VP Eric Drape sold 173,261 shares of the business’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $13.05, for a total value of $2,261,056.05. Following the sale, the vice president now owns 1 shares of the company’s stock, valued at approximately $13.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Mark Sabag sold 100,000 shares of the company’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $13.52, for a total value of $1,352,000.00. Following the completion of the sale, the executive vice president now owns 382,590 shares of the company’s stock, valued at approximately $5,172,616.80. The disclosure for this sale can be found here. Insiders sold 358,972 shares of company stock worth $4,739,820 in the last 90 days. Corporate insiders own 0.55% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on TEVA shares. The Goldman Sachs Group boosted their price target on Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the stock a “neutral” rating in a research note on Monday, February 5th. Barclays increased their price objective on shares of Teva Pharmaceutical Industries from $15.00 to $17.00 and gave the stock an “overweight” rating in a research note on Monday, February 5th. Jefferies Financial Group raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and upped their target price for the company from $10.00 to $14.00 in a report on Tuesday, January 23rd. StockNews.com raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 1st. Finally, JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 price objective for the company in a research note on Friday, March 8th. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $13.78.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.